Targets for vascular protection after acute ischemic stroke
- PMID: 15284446
- DOI: 10.1161/01.STR.0000138023.60272.9e
Targets for vascular protection after acute ischemic stroke
Abstract
Background: Vascular damage caused by cerebral ischemia leads to edema, hemorrhage formation, and worsened outcomes in ischemic stroke patients. Therapeutic interventions need to be developed to provide vascular protection. The purpose of this review is to identify the pathophysiologic processes involved in vascular damage after ischemia, which may lead to strategies to provide vascular protection in ischemic stroke patients.
Summary of comment: The pathologic processes caused by vascular injury after an occlusion of a cerebral artery can be separated into acute (hours), subacute (hours to days), and chronic (days to months). Targets for intervention can be identified for all 3 stages. Acutely, superoxide is the predominant mediator, followed by inflammatory mediators and proteases subacutely. In the chronic phase, proapoptotic gene products have been implicated.
Conclusions: Pharmacological agents designed to target specific pathologic and protective processes affecting the vasculature should be used in clinical trials of vascular protection after acute ischemic stroke.
Similar articles
-
Tactics for vascular protection after acute ischemic stroke.Pharmacotherapy. 2005 Mar;25(3):387-95. doi: 10.1592/phco.25.3.387.61592. Pharmacotherapy. 2005. PMID: 15843286 Review.
-
Vascular protection in brain ischemia.Cerebrovasc Dis. 2006;21 Suppl 2:21-9. doi: 10.1159/000091700. Epub 2006 May 2. Cerebrovasc Dis. 2006. PMID: 16651811
-
Minocycline and hypothermia for reperfusion injury after focal cerebral ischemia in the rat: effects on BBB breakdown and MMP expression in the acute and subacute phase.Brain Res. 2008 Jan 10;1188:198-206. doi: 10.1016/j.brainres.2007.10.052. Epub 2007 Nov 26. Brain Res. 2008. PMID: 18031717
-
Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.Stroke. 2003 Aug;34(8):e109-37. doi: 10.1161/01.STR.0000082721.62796.09. Epub 2003 Jul 17. Stroke. 2003. PMID: 12869717
-
Recanalization and reperfusion therapies for acute ischemic stroke.Cerebrovasc Dis. 2009;27 Suppl 1:162-7. doi: 10.1159/000200455. Epub 2009 Apr 3. Cerebrovasc Dis. 2009. PMID: 19342847 Review.
Cited by
-
Nox2 oxidase activity accounts for the oxidative stress and vasomotor dysfunction in mouse cerebral arteries following ischemic stroke.PLoS One. 2011;6(12):e28393. doi: 10.1371/journal.pone.0028393. Epub 2011 Dec 2. PLoS One. 2011. PMID: 22164282 Free PMC article.
-
Blood-brain barrier dysfunction in epileptogenesis of the temporal lobe.Epilepsy Res Treat. 2011;2011:143908. doi: 10.1155/2011/143908. Epub 2011 Jun 7. Epilepsy Res Treat. 2011. PMID: 22937228 Free PMC article.
-
Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model.PLoS One. 2007 Jan 17;2(1):e156. doi: 10.1371/journal.pone.0000156. PLoS One. 2007. PMID: 17225860 Free PMC article.
-
Endothelium-targeted overexpression of Krüppel-like factor 11 protects the blood-brain barrier function after ischemic brain injury.Brain Pathol. 2020 Jul;30(4):746-765. doi: 10.1111/bpa.12831. Epub 2020 Apr 14. Brain Pathol. 2020. PMID: 32196819 Free PMC article.
-
An In Vitro Thrombolysis Study Using a Mixture of Fast-Acting and Slower Release Microspheres.Pharm Res. 2016 Jul;33(7):1552-63. doi: 10.1007/s11095-016-1897-1. Epub 2016 Mar 10. Pharm Res. 2016. PMID: 26964547
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials